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Plasma cytokine levels predict mortality in patients with acute
renal failure.
Background. Critically ill patients with acute renal fail-
ure (ARF) experience a high mortality rate. Animal and hu-
man studies suggest that proinflammatory cytokines lead to
the development of a systemic inflammatory response syn-
drome (SIRS), which is temporally followed by a counter anti-
inflammatory response syndrome (CARS). This process has not
been specifically described in critically ill patients with ARF.
Methods. The Program to Improve Care in Acute Renal Dis-
ease (PICARD) is a prospective, multicenter cohort study de-
signed to examine the natural history, practice patterns, and
outcomes of treatment in critically ill patients with ARF. In a
subset of 98 patients with ARF, we measured plasma proin-
flammatory cytokines [interleukin (IL)-1b , IL-6, IL-8, tumor
necrosis factor-a (TNF-a)], the acute-phase reactant C-reactive
protein (CRP), and the anti-inflammatory cytokine IL-10 at
study enrollment and over the course of illness.
Results. When compared with healthy subjects and end-stage
renal disease patients on maintenance hemodialysis, patients
with ARF had significantly higher plasma levels of all mea-
sured cytokines. Additionally, the proinflammatory cytokines
IL-6 and IL-8 were significantly higher in nonsurvivors versus
survivors [median 234.7 (interdecile range 64.8 to 1775.9) pg/mL
vs. 113.5 (46.1 to 419.3) pg/mL, P = 0.02 for IL-6; 35.5 (14.1 to
237.9) pg/mL vs. 21.2 (8.5 to 87.1) pg/mL, P = 0.03 for IL-8]. The
anti-inflammatory cytokine IL-10 was also significantly higher
in nonsurvivors [3.1 (0.5 to 41.9) pg/mL vs. 2.4 (0.5 to 16.9) pg/
mL, P = 0.04]. For each natural log unit increase in the levels
of IL-6, IL-8, and IL-10, the odds of death increased by 65%,
54%, and 34%, respectively, corresponding to increases in rel-
ative risk of approximately 30%, 25%, and 15%. The presence
or absence of SIRS or sepsis was not a major determinant of
plasma cytokine concentration in this group of patients.
Conclusion. There is evidence of ongoing SIRS with con-
comitant CARS in critically ill patients with ARF, with higher
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levels of plasma IL-6, IL-8, and IL-10 in patients with ARF who
die during hospitalization. Strategies to modulate inflammation
must take into account the complex cytokine biology in patients
with established ARF.
Severely ill patients in the intensive care unit (ICU)
setting experience a high rate of mortality, and this risk is
compounded when their course is complicated by acute
renal failure (ARF). Published studies estimate that 5%
to 20% of ICU patients experience an episode of ARF
during the course of their illness, often accompanied by
multiorgan dysfunction [1–3]. Despite advances in sup-
portive care and innovations in renal replacement ther-
apies over the past three decades, the mortality rate for
these patients remains high, with most studies citing death
rates in excess of 50% [4, 5]. The association between
ARF and death in ICU patients appears to be indepen-
dent of other complications, suggesting that patients die
in part from, and not only with, ARF [6–8].
Severe illness of almost any etiology is accompanied
by a generalized host inflammatory response. This has
been referred to as the systemic inflammatory response
syndrome (SIRS) [9, 10]. Central to this process is the
release of a cascade of potent inflammatory mediators
into the systemic circulation, including tumor necrosis
factor-a (TNF-a), interleukin-1b (IL-1b), and IL-6. It
is now recognized that this intense proinflammatory re-
action is often followed temporally by a compensatory
anti-inflammatory response syndrome (CARS), during
which time anti-inflammatory cytokines, including IL-10,
are liberated into the bloodstream [10]. In some clinical
settings, including uremia and sepsis, dysregulation of the
inflammatory process is characterized by simultaneous
release of both proinflammatory and anti-inflammatory
mediators [11]. The dysregulation of the inflammatory
response in septic and critically ill patients has been
implicated as an important mechanism underlying the
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development of multiple organ system dysfunction, sep-
tic shock, and death.
Given the clear association between persistent activa-
tion of the inflammatory response and multisystem organ
failure, several studies have examined the prognostic role
of plasma levels of the various inflammatory mediators
in predicting outcomes in critically ill patients in general
[12–14]. However, few studies have focused on severely ill
patients with ARF. We hypothesized that extensive im-
mune dysregulation would be associated with all-cause
mortality in critically ill patients with ARF, based on the
exceedingly high mortality rates observed in this patient
population, and the complex metabolic derangements in-
duced by reduction in glomerular filtration rate, hyper-
catabolism, and the effects of dialysis.
METHODS
Study cohort
This study was performed as a part of the Program
to Improve Care in Acute Renal Disease (PICARD)
network. The PICARD study is a prospective observa-
tional cohort examining the natural history, practice pat-
terns, and outcomes of treatment in critically ill patients
with ARF, conducted at five academic medical centers in
the United States (Cleveland Clinic Foundation, Cleve-
land, Ohio; Maine Medical Center, Portland, Maine;
Vanderbilt University, Nashville, Tennessee; University
of California, San Diego, California; University of Cali-
fornia, San Francisco, California). The study period was
from February 1, 1999 to August 31, 2001. All adult (age
≥18 years) ICU patients with ARF in whom a nephrol-
ogy service consultation was received were considered
for the study. ARF was defined using standard laboratory
parameters. For patients with no prior history of kidney
disease, or baseline creatinine values of <1.5 mg/dL, ARF
was defined by an increase in serum creatinine of at least
0.5 mg/dL occurring over a 48-hour period. For those pa-
tients with pre-existing chronic renal insufficiency (base-
line creatinine values ≥1.5 mg/dL), ARF was defined by a
rise in serum creatinine of ≥1 mg/dL from baseline occur-
ring over 48 hours. Exclusion criteria included previous
dialysis, kidney transplantation, ARF from urinary tract
obstruction or from hypovolemia responsive to fluids, as
well as prisoners and pregnant patients. The study was
approved by the Institutional Review Board of each par-
ticipating hospital, and informed consent was obtained
from all study participants or their next-of-kin.
As a substudy of PICARD, patients enrolled at
Vanderbilt University Medical Center and Maine Med-
ical Center were asked to undergo serial measurements
of biomarkers of inflammation. A total of 414 ARF cases
from these two centers were initially evaluated, with
201 (49%) meeting entry criteria. This particular study
required an additional consent requesting blood sam-
pling for cytokine determination, and the 98 patients who
agreed to sign the additional consent form comprised the
analytic sample. Of these participants, 25 (26%) were at
Maine Medical Center and 73 (74%) were at Vander-
bilt University Medical Center. Patients were followed
prospectively from the time of initial nephrology service
consultation until death or hospital discharge. We com-
pared results obtained in patients with ARF with healthy
control patients (N = 48) and patients with end-stage
renal disease (ESRD) on maintenance hemodialysis
(N = 42).
Clinical and laboratory data
The study consisted of baseline and serial measure-
ments of biomarkers of inflammation beginning at the
time of nephrology consultation and each week there-
after over the course of hospitalization. Renal function
was assessed daily from records of urine output, blood
urea nitrogen (BUN) level, and serum creatinine level.
Patients were considered to be oliguric when urine out-
put fell below 400 mL per 24 hours. The origin of ARF was
classified as ischemic, nephrotoxic, or multifactorial acute
tubular necrosis, multisystem disease (i.e., systemic lupus
erythematosus, rapidly progressive glomerulonephritis),
or uncertain. Complete recovery of renal function was
defined as the return of serum creatinine to <2.0 mg/dL,
or return to within 20% of baseline creatinine concentra-
tion for patients with underlying chronic renal disease.
Recovery was deemed to be partial when the above
conditions were not met, but the patient was no
longer dialysis-dependent. Vital signs, hemodynamic data
(where available), and general laboratory data were
recorded for the first ICU day and each day from the
time of nephrology consultation, and generic severity-of-
illness scores were computed from these variables. At the
time of initial nephrology assessment, patients were eval-
uated for the presence of SIRS, sepsis, or septic shock as
defined by American College of Chest Physicians/Society
of Critical Care Medicine guidelines [15]. Specifically,
SIRS was defined as the systemic inflammatory response
to an unspecified stimulus manifested by the presence
of two or more of the following: (1) a body tempera-
ture greater than 38◦C or less than 36◦C; (2) a heart rate
greater than 90 beats per minute; (3) on a ventilator, or
tachypnea, manifested by a respiratory rate greater than
20 breaths per minute, or hyperventilation, as indicated
by a PaCO2 of less than 32 mm Hg; and (4) a white
blood cell count greater than 12,000/mm3 or less than
4,000/mm3, or the presence of more than 10% immature
neutrophils. Sepsis included the above criteria when an
infectious source was documented or strongly suspected.
For our study purposes, sepsis and severe sepsis (sepsis
associated with organ dysfunction, hypoperfusion, or hy-
potension) were considered in the same category, as all
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patients included in the study had evidence of renal or-
gan dysfunction. Septic shock was defined as sepsis with
hypotension, despite adequate fluid resuscitation, along
with the presence of perfusion abnormalities.
Biomarkers of inflammation
Inflammatory markers followed during the study in-
cluded the proinflammatory cytokines IL-1b , IL-6, IL-8,
and TNF-a; the acute-phase reactant C-reactive protein
(CRP); and the anti-inflammatory cytokine IL-10. Base-
line venous blood samples for cytokine determination
were collected within 48 hours of nephrology consulta-
tion for ARF study subjects and predialysis for ESRD
patients on maintenance hemodialysis. Blood samples
were taken into EDTA tubes and clot activator tubes
for plasma and serum separation, respectively. Sam-
ples were immediately centrifuged, and the plasma and
serum stored at−70◦C until analysis. Cytokine concentra-
tions were measured in duplicate by enzyme-linked im-
munosorbent assay (ELISA) with kits from BioSource
International (Camarillo, CA, USA). IL-1b , IL-6, and
TNF-a were measured in plasma, and IL-8 and IL-10 in
serum. The detectable limits and interassay coefficients
of variation for the cytokines were 2.0 pg/mL and 5% for
IL-1b , 2.0 pg/mL and 6% for IL-6, 0.7 pg/mL and 5%
for IL-8, 1.0 pg/mL and 3% for IL-10, and 3.0 pg/mL and
10% for TNF-a, respectively. Serum CRP was measured
using high-sensitivity nephelometry (Dade Behring, Inc.,
Newark, DE, USA).
Analysis plan
We focused on determining the associations among
biomarkers of inflammation with mortality. The primary
outcome measure was all-cause in-hospital mortality,
with ICU mortality analyzed as a secondary outcome.
Demographic data such as age, sex, and race were also
tabulated. IL-1b and IL-10 levels below the reference
laboratory’s limit of detection (<2 pg/mL for IL-1b and
<1 pg/mL for IL-10) were assigned values of 1.1 and
0.5 pg/mL, respectively, for statistical analysis. Addition-
ally, the distributions of IL-1b , IL-6, IL-8, IL-10, and
TNF-a were highly skewed, and values for these inflam-
matory markers were natural log-transformed before in-
ference testing.
For univariate analysis of single time point data, com-
parisons among ARF patients and control patients, as
well as among survivors and nonsurvivors, were assessed
using the Student t test or Mann-Whitney U test for
continuous variables; discrete data were analyzed by
Pearson v 2 test or Fisher exact test. Logistic regres-
sion was employed to evaluate independent predictors
of mortality. Odds ratios (OR) and 95% CI were de-
rived from model parameter coefficients and standard
errors, respectively. In multivariable analyses, we ad-
justed for confounding by age, sex, and race. We also
evaluated whether other nondemographic predictors of
mortality confounded the cytokine-mortality relation, in-
cluding signs of sepsis and generic severity of illness
scores [e.g., Acute Physiology and Chronic Health Eval-
uation (APACHE) III]. The trends of the inflamma-
tory markers over the time were estimated using the
restricted/residual maximum likelihood (REML)-based
mixed effect model to adjust for the intra-correlation ef-
fect for the patients who had multiple measurements. The
model reported herein was selected based on Akaike’s In-
formation Criterion (AIC) and Schwarz’s Bayesian Cri-
terion (BIC) [16]. Results are expressed as mean ± SD or
median and range, where appropriate. All tests of signif-
icance were two-sided, and differences were considered
statistically significant with P value < 0.05. SAS version
8.2 (Statistical Analysis System for Windows; SAS Insti-
tute, Inc., Cary, NC, USA) was used for data analyses.
RESULTS
Patient characteristics
The demographic and clinical characteristics for the
98 patients at the time of nephrology consultation are
summarized in Table 1. The mean age (±SD) of the to-
tal study cohort was 60.3 (±15.7) years, with 59% male
patients and 96% white patients. The predominant etiol-
ogy of ARF based on clinical presumption was ischemic
(47%) or multifactorial acute tubular necrosis (40%). The
mean (±SD) BUN and creatinine at the time of nephrol-
ogy consultation were 60.6 (±30.1) mg/dL and 3.2 (±1.3)
mg/dL, respectively, and median urine output was 927.5
[interdecile range 102 to 3178] mL per 24 hours. A num-
ber of the participants were classified as having SIRS
(5%), sepsis (25%), or septic shock (3%) at the time of
nephrology consultation. The average number of nonre-
nal organ systems in failure at the time of initial assess-
ment by the nephrology consultant was 2.0 (±1.0), and
these were primarily respiratory failure (74%) and car-
diovascular failure (63%). Notably, only three patients in
the cohort had isolated renal failure, without additional
organ systems in failure, at the time of renal consultation.
Fifty-five patients received renal replacement therapy,
predominantly intermittent hemodialysis (43 patients),
during the course of their illness, and 50% of the total co-
hort recovered renal function (19% with partial recovery
and 31% with complete recovery) before hospital dis-
charge or death (Table 2).
Healthy control patients consisted of 48 nonpregnant,
generally well individuals with no known cardiovascular
disease or diabetes mellitus. This subset was composed
of 30 women (62%) and 18 men (38%), the majority
of whom were white (92%). The mean age (±SD) for
healthy control patients was 49.1 (±16.1) years (P < 0.001
vs. ARF patients).
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Table 1. Patient demographics and clinical features as assessed on the day of nephrology consultation according to survival status
Total Survivors Nonsurvivors
Demographics and history N = 98 N = 54 N = 44 P value
Age years 60.3 (15.7) 58.5 (16.9) 62.6 (14.0) NS
Male % 59.2 55.6 63.6 NS
White % 95.9 96.3 95.5 NS
Diabetes mellitus% 35.7 35.2 36.4 NS
ARF on CRI % 29.9 28.3 31.8 NS
History of cardiac disease % 49.0 40.7 59.1 0.07
History of liver disease % 16.3 14.8 18.2 NS
Surgical % 57.8 64.0 50.0 NS
Etiology of ARF %
Ischemic 46.9 50.0 43.2 NS
Nephrotoxic 8.2 9.3 6.8 NS
Multisystem 1.0 1.9 0.0 NS
Multifactorial 39.8 35.2 45.5 NS
Unknown 4.1 3.7 4.5 NS
Renal function indicators
Blood urea nitrogen mg/dL 60.6 (30.1) 54.7 (27.7) 67.1 (31.6) 0.06
Creatinine mg/dL 3.2 (1.3) 3.2 (1.4) 3.3 (1.1) NS
Median urine output (interdecile range) mL 927.5 (102–3178) 1285.0 (255–4130) 425.0 (41–2352) 0.001
Oliguria % 27.6 15.7 44.2 0.002
SIRS % 5.1 8.0 2.6 NS
Sepsis or septic shock % 28.6 34.0 28.9 NS
Organ system failure %
Respiratory 73.6 68.8 79.5 NS
Cardiac 62.5 62.5 62.5 NS
Hepatic 23.0 18.8 28.2 NS
Hematologic 23.0 25.0 20.5 NS
Central nervous system 23.0 22.9 23.1 NS
Severity-of-illness scores
APACHE II 23.0 (6.4) 22.7 (5.9) 23.4 (7.0) NS
APACHE III 77.7 (18.5) 72.1 (16.5) 84.3 (18.8) 0.002
SAPS II 53.8 (15.7) 49.7 (12.4) 58.7 (17.9) 0.04
SOFA 5.6 (2.7) 5.2 (2.5) 6.2 (2.9) 0.08
Abbreviations are: ARF, acute renal failure; CRI, chronic renal insufficiency; SIRS, systemic inflammatory response syndrome; APACHE, Acute Physiology and
Chronic Health Evaluation; SAPS, simplified acute physiology score; SOFA, sequential organ failure assessment. Data are presented as mean (SD) unless otherwise
indicated. P values are for survivors vs. nonsurvivors.
Table 2. Patient outcomes
Survivors Nonsurvivors P value
Hemodialysis % 40.7 75.0 0.001
Renal function recovery %
Partial 24.5 13.6 NS
Complete 54.7 4.5 <0.001
Mortality %
Hospital mortality 44.9
Mortality day, median 10.5 (4–36)
(interdecile range)
ICU mortality 37.8
30-day mortality 36.7
ICU, intensive care unit.
Forty-two patients on maintenance hemodialysis
(≥12 months) served as additional controls. They were
of similar age (mean ± SD, 58.4 ± 17.3 vs. 60.3 ± 15.7
for ARF patients, P = 0.52) and sex distributions (62%
male vs. 59% male, P = 0.76) to the study participants
with ARF. The percentage of black subjects with ESRD
was much higher than in the cohort with ARF (62% vs.
4%, P < 0.001). Twenty-nine percent of the ESRD group
had diabetes mellitus (P = 0.42 vs. ARF patients). The
mean (±SD) monthly dose of dialysis delivered for the
ESRD group at the time of cytokine determination was
1.6 (±0.3) for Kt/V and 75.3 (±8.0) for urea reduction
ratio.
As noted in the Methods section, there was a group
of patients from both centers who refused consent for
cytokine analysis (“refusers,” N = 103), but who were in-
cluded in the overall PICARD study. A comparison of the
demographic characteristics showed that refusers were
slightly older than study participants (mean age ± SD,
64.8 ± 14.1 years vs. 60.3 ± 15.7 years, P = 0.04). However,
there were no significant differences in sex, race/ethnicity,
history of diabetes mellitus, or renal parameters, includ-
ing serum creatinine, BUN, and presence of oliguria, at
the time of consultation. Both groups had, on average,
two organ systems in failure in addition to ARF upon
initial nephrology evaluation (P = 0.64). A similar frac-
tion of subjects in both groups (56% of participants and
46% of refusers, P = 0.15) underwent renal replacement
therapy over the course of the study. In-hospital mor-
tality was statistically higher in the study participants
than the refusers (45% vs. 30%, P = 0.03), although
recovery of renal function was comparable in the two
groups.
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Fig. 1. Cytokine values for study participants
at the time of nephrology consultation versus
healthy subjects and end-stage renal disease
(ESRD) control subjects (only IL-6, IL-10,
and CRP available). Bars and error bars rep-
resent mean ± SEM for each time point.
∧P = 0.031 for interleukin (IL)-1b (ARF
study patients vs. healthy subjects); P < 0.001
for all other comparisons (ARF study patients
vs. healthy subjects and ARF study patients vs.
ESRD control patients). §CRP in mg/L.
Overall survival
The in-hospital mortality rate for the study cohort was
45%. The median survival time for those patients who
died was 10.5 days (interdecile range 4 to 36 days). Like-
wise, the ICU mortality rate for the study cohort was 38%,
indicating that the majority of deaths occurred in the ICU
setting. Table 1 displays the demographic and clinical fea-
tures according to survival status. Neither demographic
characteristics, presumed etiology of ARF, nor serum in-
dicators of renal function were associated with mortality.
Not surprisingly, mortality rates were higher among those
patients who were oliguric (70% vs. nonoliguric mortality
of 36%, P = 0.002) and for those who required dialysis
(60% vs. 26%, P =0.001). Mean APACHE III and Simpli-
fied Acute Physiology Score (SAPS) II scores as assessed
at the time of nephrology consultation were significantly
higher among nonsurvivors compared with patients who
survived to hospital discharge (84.3 vs. 72.1, P = 0.004
and 58.7 vs. 49.7, P = 0.04 for APACHE III and SAPS II
scores, respectively).
Plasma cytokine levels are elevated at the time
of nephrology consultation and predict mortality
Baseline cytokine and CRP values determined from
blood obtained within 48 hours of study entry are de-
picted in Figure 1. As illustrated, critically ill patients with
ARF had marked simultaneous increases in plasma lev-
els of all cytokines (P < 0.05 for IL-1b ; P < 0.001 for IL-6,
IL-8, IL-10, and TNF-a) and CRP (P < 0.001) when com-
pared with healthy control subjects. Likewise, the values
of IL-6, IL-10, and CRP were also 10- to 20-fold higher in
the critically ill ARF patients compared with ESRD pa-
tients on maintenance hemodialysis (P < 0.001 for all).
The relationships among baseline cytokine and CRP con-
centrations of study participants and various physiologic
variables as assessed at the time of nephrology consulta-
tion are presented in Table 3.
Table 3. Correlations among baseline inflammatory biomarkers and
physiologic variables measured on the day of nephrology consultation
IL-1b Il-6 IL-8 IL-10 TNF-a CRP
Age −.089 .014 −.067 .028 .037 .219
.398 .892 .533 .797 .723 .063
BUN .316 .004 .234 .306 .275 −.220
.004a .972 .038a .006a .011a .086
Creatinine −.001 −.012 .132 .023 .147 .015
.996 .918 .243 .840 .176 .909
UOP −.136 −.221 −.295 −.258 −.224 −.058
.204 .038a .006a .016a .032a .636
APACHE III .016 .142 .458 .186 .289 −.006
.889 .208 <.001a .104 .008a .963
SAPS II .127 .021 .310 .405 .203 .029
.390 .888 .028a .004a .157 .863
Abbreviations are: IL, interleukin; TNF, tumor necrosis factor; CRP, C-reactive
protein; BUN, blood urea nitrogen; UOP, urine output; APACHE, Acute Physiol-
ogy and Chronic Health Evaluation; SAPS, simplified acute physiology score. Val-
ues presented are Pearson correlation coefficients (upper) and P values (lower).
aDenotes statistically significant correlations. Data that did not fit a normal dis-
tribution were log transformed before analysis (IL-1b , IL-6, IL-8, IL-10, TNF-a,
creatinine, and urine output).
Several cytokines, reflecting both the proinflammatory
and anti-inflammatory cascades, were elevated at base-
line in nonsurvivors compared with those patients who
survived to hospital discharge. Specifically, the proin-
flammatory cytokines IL-6 and IL-8 were significantly
higher in nonsurvivors versus survivors [median 234.7
(interdecile range 64.8 to 1775.9) pg/mL vs. 113.5 (46.1 to
419.3) pg/mL, P = 0.02 for IL-6; 35.5 (14.1 to 237.9) pg/mL
vs. 21.2 (8.5 to 87.1) pg/mL, P = 0.03 for IL-8]. Similarly,
the median value for the anti-inflammatory cytokine IL-
10 was 3.1 (0.5 to 41.9) pg/mL for nonsurvivors compared
with 2.4 (0.5 to 16.9) pg/mL for survivors (P = 0.04). Each
natural log unit increase of IL-6, IL-8, and IL-10 was as-
sociated with an OR (95% CI) of fatal outcome of 1.65
(1.09 to 2.49), 1.54 (1.03 to 2.30), and 1.34 (1.01 to 1.80),
respectively. Figure 2 illustrates the risk profiles for the
inflammatory biomarkers according to quartiles. Notably,
for both IL-6 and IL-10, baseline cytokine values above
the 25th percentile were associated with a progressively
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Table 4. Baseline plasma cytokine levels according to presence of
SIRS, sepsis, or septic shock at the time of nephrology consultation
No SIRS/no sepsis SIRS/sepsis/septic shock
N = 63 N = 34 P value
IL-1b 2.0 (1.1–20.4) 1.1 (1.1–9.2) 0.24
IL-6 158.2 (30.9–932.0) 156.9 (67.8–575.4) 0.99
IL-8 24.1 (8.0–245.3) 34.8 (13.8–120.6) 0.40
IL-10 2.4 (0.5–26.5) 3.4 (0.5–28.2) 0.23
TNF-a 47.4 (24.3–99.1) 67.8 (36.5–143.1) 0.001
CRP 102.6 (28.8–275.8) 148.3 (67.8–271.1) 0.08
Abbreviations are: IL, interleukin; TNF, tumor necrosis factor; CRP,
C-reactive protein; SIRS, systemic inflammatory response syndrome. Values are
median (interdecile range) for each variable. Cytokines are expressed as pg/mL;
CRP is expressed as mg/L.
higher risk of mortality (P = 0.02 and P = 0.05 for IL-6
and Il-10 trends, respectively; P = 0.04 for IL-8 trend, data
not shown). Although numerically higher, the difference
in median values for IL-1b , TNF-a, and CRP between the
two groups did not reach statistical significance. The asso-
ciations among inflammatory markers and ICU mortality
were similar to those with in-hospital mortality (data not
shown).
The presence or absence of SIRS or sepsis was not a ma-
jor determinant of plasma cytokine concentration in this
subgroup of critically ill ARF patients. Table 4 depicts the
baseline plasma concentrations of the proinflammatory
and anti-inflammatory markers examined in this study by
SIRS/sepsis status as assessed on the day of nephrology
consultation. TNF-a was consistently higher in patients
with SIRS, sepsis, or septic shock compared with patients
without these conditions (P = 0.001). No significant dif-
ferences were observed in the remaining plasma cytokine
values among the groups. Likewise, the presence of SIRS,
sepsis, or septic shock was not independently associated
mortality (P = 0.24).
In multivariable analysis of cytokines as predictors of
in-hospital mortality, adjustment for demographic factors
(age, race, sex) and sepsis status did not extinguish the sig-
nificant associations among baseline IL-6, IL-8, and IL-
10 values and mortality (P = 0.02 for IL-6, P = 0.03 for
IL-8, and P = 0.05 for IL-10). Likewise, when adjusted
for severity of illness (APACHE III), IL-6 remained an
independent predictor of in-hospital mortality (P = 0.04),
while IL-8 and IL-10 sustained marginal significance
(P = 0.06 and P = 0.07 for IL-8 and IL-10, respectively).
Interestingly, after the predictive value of cytokines were
adjusted for urine output on the day of nephrology con-
sultation, which itself was significantly associated with
in-hospital death, only IL-6 maintained a trend toward
significance (P = 0.08), while IL-8 and IL-10 were no
longer independently associated with mortality (P = 0.23
and P = 0.28, respectively).
Levels of inflammatory markers decrease over time
To assess the relationship between changes in inflam-
matory markers over time and in-hospital mortality, we
measured cytokine and CRP values at weekly intervals
from study entry in patients who remained in the ICU.
The inflammatory biomarkers were generally lower in
survivors compared with nonsurvivors over serial mea-
surements, with all but IL-1b and CRP attaining statisti-
cal significance (Table 5). The proinflammatory cytokine
IL-6 and the anti-inflammatory cytokine IL-10 showed
significant decreases over the study period (P = 0.01
and P = 0.04, respectively), and the differences in these
cytokine levels between survivors and nonsurvivors re-
mained statistically significant (P = 0.001 and P = 0.04,
respectively, for IL-6 and IL-10). This phenomenon is
represented graphically for IL-6 in Figure 3. There were
also significant declines in overall IL-1b and CRP levels,
while IL-8 and TNF-a levels appeared to change little
over time. These trends were not affected by whether or
not patients received renal replacement therapy.
DISCUSSION
The current study was designed to evaluate whether
biomarkers of inflammation were associated with mortal-
ity in a cohort of 98 critically ill patients with ARF. At the
time of nephrology consultation, the proinflammatory cy-
tokines IL-6 and IL-8, as well as the anti-inflammatory
cytokine IL-10 were significantly higher in nonsurvivors
than in those patients who survived to hospital discharge.
For each natural log unit increase in levels of IL-6, IL-8,
and IL-10, the odds of death increased by point estimates
of 65%, 54%, and 34%, respectively, corresponding to in-
creases in relative risk of approximately 30%, 25%, and
15%, respectively [17]. The association between cytokine
concentrations and in-hospital mortality was maintained
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Table 5. Relationship of changes in inflammatory markers over time
to in-hospital survival
N Survivors Nonsurvivors P value
IL-1b pg/mL 0.80a
Baseline 93 1.1 (1.1–11.1) 3.0 (1.1–19.0) <0.001b
Week 1 29 9.9 (1.1–49.6) 17.8 (1.1–28.9)
Week 2 14 27.6 (1.1–61.8) 30.7 (5.0–33.2)
IL-6 pg/mL 0.001a
Baseline 91 113.5 (46.1–419.3) 234.7 (64.8–1775.9) 0.01b
Week 1 34 90.7 (22.4–735.6) 173.1 (59.9–1349.0)
Week 2 15 63.0 (29.9–454.5) 252.5 (34.2–564.0)
IL-8 pg/mL 0.006a
Baseline 90 21.2 (8.5–87.1) 35.5 (14.1–237.9) 0.70b
Week 1 33 28.3 (7.7–85.4) 45.7 (18.3–182.7)
Week 2 17 21.3 (7.2–51.3) 40.4 (20.5–114.6)
IL-10 pg/mL 0.04a
Baseline 90 2.4 (0.5–16.9) 3.1 (0.5–41.9) 0.04b
Week 1 33 1.8 (0.5–13.9) 2.9 (1.0–13.9)
Week 2 16 2.2 (0.5–65.6) 2.2 (1.2–7.2)
TNF-a pg/mL 0.03a
Baseline 96 50.7 (26.6–120.3) 58.7 (29.6–105.6) 0.66b
Week 1 33 45.9 (29.0–73.0) 67.9 (37.7–123.7)
Week 2 16 58.3 (30.6–101.7) 77.8 (57.7–203.8)
CRP mg/L 0.36a
Baseline 73 109.8 (38.2–233.1) 122.4 (30.8–328.4) <0.001b
Week 1 31 66.0 (22.6–270.9) 65.7 (9.4–253.9)
Week 2 15 53.2 (6.9–184.2) 124.4 (57.0–153.8)
Abbreviations are: IL, interleukin; TNF, tumor necrosis factor; CRP, C-
reactive protein. Values are presented as median (interdecile range). Data were
analyzed using the mixed effect model; values for IL-6, IL-8, IL-10, and TNF-a
were log transformed before analysis due to the non-normal distribution of these
variables. N denotes the number of study patients at each time point.
aDenotes P values between survivors and nonsurvivors over the course of
multiple measurements.
bDenotes P values for changes in cytokine levels over time.
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Fig. 3. Changes in plasma interleukin (IL)-6 concentrations over three
weeks among survivors and nonsurvivors. Points and error bars repre-
sent mean ± SEM for each time point.
even after adjusting for demographics (age, race, sex) and
sepsis status.
Cytokines are proteins with potent pleiotrophic bio-
logic effects at picomolar concentrations [18]. Proinflam-
matory cytokines, including TNF-a, IL-1b , IL-6, and IL-8
are required for the initiation of an effective inflamma-
tory response to infection and/or tissue injury. Proinflam-
matory cytokines are able to induce each other in a series
of cascade events, thereby resulting in synergistic poten-
tiation of pathobiologic effects. High concentrations of
proinflammatory cytokines have been reported to cor-
relate with the prognosis of sepsis and the development
of multiorgan dysfunction syndrome. In animal models,
infusion of high concentrations of proinflammatory cy-
tokines can lead directly to the development of multior-
gan system failure [19]. Several, but not all, studies have
suggested that levels of circulating proinflammatory cy-
tokines can be used as a measure of severity of illness
and/or as a prognostic marker for patients with sepsis
and multiorgan system failure.
There are, however, important distinctions between the
present study and the body of literature reporting plasma
cytokines in critically ill patients, especially patients with
sepsis. In many sepsis studies, the proinflammatory cy-
tokines IL-1 and TNF-a predict mortality, while in the
present study we did not observe such a relationship. In-
stead, the significant predictors of survival were IL-6 and
IL-8, often considered secondary inflammatory cytokines
that are more distal in inflammatory cascades than IL-1
or TNF-a. It is noteworthy that an association between
IL-6 and mortality has also been demonstrated in pa-
tients with chronic kidney disease [20, 21]. These findings
suggest that renal failure may in and of itself confer an
altered cytokine profile, even in the context of critical ill-
ness. Another potential explanation for this discrepancy
between our study and previous studies in patients with
sepsis may be the timing of cytokine determination in the
overall course of illness. The fact that earlier markers of
inflammation, namely IL-1 and TNF-a, were not associ-
ated with mortality in our cohort, while those later in the
inflammatory cascade (i.e., Il-6 and IL-8) were may indi-
cate that at the time of nephrology consultation and blood
sampling, the patients had been inflamed for an extended
period. Finally, the alterations in cytokine metabolism
caused by underlying disease(s) might account for our
observed results [22].
In this study we also measured plasma levels of the pro-
totypical anti-inflammatory cytokine IL-10. Interleukin-
10 is known to counter-regulate the cascade of
proinflammatory cytokines that develop as a result of
tissue injury and as part of the acute-phase reaction,
including TNF-a, IL-1, and IL-6. Several previously re-
ported studies demonstrate that in the sepsis syndrome,
elevated plasma IL-10 levels are associated with poor
survival, a finding similar to the present study of criti-
cally ill patients with ARF [23, 24]. Interleukin-10 can
directly inhibit the monocyte inflammatory response to
endotoxin and other stimuli, and a number of studies
have demonstrated that monocyte hyporesponsiveness
in sepsis and multiorgan dysfunction syndromes in criti-
cally ill patients is also strongly associated with mortality
[25]. The increase in IL-10 and other anti-inflammatory
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cytokines after an acute-phase inflammatory response
has been termed the “counter anti-inflammatory re-
sponse syndrome,” or CARS. Data from the present study
would suggest that in critically ill patients with ARF, dys-
regulation of proinflammatory and anti-inflammatory cy-
tokine networks may proceed in parallel and the overall
degree of cytokine network disruption may be an impor-
tant prognostic indicator.
A surprising finding in this study is that plasma cytokine
levels did not differ substantially between patients with
or without the diagnosis of sepsis. ARF frequently de-
velops as a complication of sepsis, and the prevalence of
ARF in patients who develop sepsis ranges from 9% to
40% in published studies [26]. Patients with ARF and sep-
sis are also reputed to have a higher mortality rate than
nonseptic patients with ARF. Although the conventional
wisdom is that sepsis precedes ARF, data from the larger
PICARD cohort suggest that the relationship between
sepsis and ARF may be more complex than previously
appreciated [abstract; Mehta RL et al: J Am Soc Nephrol
13:246A, 2002] [27].
Another notable finding in this study is the inverse
association of baseline circulating cytokine levels with
24-hour urine output on the day of renal consultation.
While urine output may reflect the glomerular filtration
rate (GFR), it is unlikely that GFR, per se, has a sig-
nificant impact on cytokine levels in critically ill ARF
patients. Indeed, the levels of cytokines we observed in
ARF patients were several-fold higher than those ob-
tained from ESRD patients who had minimal to no resid-
ual GFR. Alternatively, the resulting volume overload
associated with a diminished urine output may itself be a
significant mediator of plasma cytokine elevation in ARF
similar to that observed in patients with congestive heart
failure, and may account for the loss of significance be-
tween cytokine concentrations and mortality when ad-
justed for the impact of urine output [28].
This study has several important limitations. The
sample size was small. While the data were collected
prospectively, the timing of consultation and subsequent
measurement of cytokines were nonuniform. Therefore,
events occurring early in the course of ARF may not have
been captured. Although levels of several cytokines were
associated with mortality, there was a large degree of in-
terpatient variability in cytokine levels. Thus, we were un-
able to establish with precision clinically relevant plasma
concentrations of cytokines that could predict outcome
or response to therapy in individual patients. Moreover,
circulating cytokines have short half-lives, and there may
be considerable intrapatient variability over time. Incor-
porating these facts, one could infer that our ability to
find a “signal” between cytokines and survival is even
more noteworthy. Finally, several investigators have sug-
gested that plasma cytokine levels may not reflect mono-
cyte responsiveness to proinflammatory stimuli and thus,
may not accurately reflect the physiologic state of the
immune mechanisms at the time that they are assayed
[29–31].
CONCLUSION
In critically ill patients with ARF, proinflammatory and
anti-inflammatory cytokines are markedly elevated in the
presence or absence of sepsis, and associated with signif-
icant and clinically meaningful increases in the risk of
death. The variable timing of assessment and the hetero-
geneous population make it impossible to reach precise
conclusions regarding the specific utility of cytokine mea-
surements in patients with ARF. However, the demon-
strated association between cytokines and mortality in
this important subset of the critically ill supports the ex-
tension of ongoing research efforts exploring the inflam-
matory state in ARF.
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